Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
ConditionParkinson's Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age30-85
SponsorXuanwu Hospital, Beijing
About this trial
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Autologous induced neural stem cell-derived DA precursor cells
Treatment groups
6 Participants
are divided into 1 treatment groupLocations
1Xuanwu Hospital Capital Medical University100053, BeijingBeijing Municipality, China
Sponsors and collaborators
Xuanwu Hospital, Beijing
Lead sponsor
Source ClinicalTrials.gov